ERBB2 and cancer: In this case, relevant clinical–pathological differences can be seen, with the total mastectomy group presenting a more advanced TNM stage (stage II–III, 78% vs 63%), fewer HER2 + cancers (15% vs 31%), and more ALND (33% vs 16%) than the BSC group.